Are We Underdiagnosing Large Vessel Vasculitis?
In this episode, Anisha Dua, MD, gives us a brief insight into the various challenges observed with large vessel vasculitis imaging.
Giant Cell Arteritis
Specimen Length, Number of Sections Linked to Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis
Researchers investigated the association between specimen length and number of sections evaluated and the diagnostic yield of temporal artery biopsy for giant cell arteritis.
Determination of Clinical Characteristics With Immunophenotyping in Large Vessel Vasculitis
In this study, researchers used immunophenotyping to explore the biomarkers associated with clinical characteristics in large vessel vasculitis.
Temporal Ultrasound May Be Useful in Giant Cell Arteritis Disease Monitoring
Researchers suggest that temporal ultrasound may be an appealing choice for monitoring disease activity in patients with cranial giant cell arteritis treated with tocilizumab.
Decrease in Giant Cell Arteritis Relapse Risk With Elevated Platelet Count, CC Promoter Polymorphism
Researchers studied the risk factors for relapse, including prednisolone clearance and glucocorticoid-induced transcript 1 promoter polymorphism (rs37972), in patients with giant cell arteritis.
Survival Predictors Identified in Patients With Biopsy-Proven Giant Cell Arteritis
Researchers evaluated the influence of disease-related findings and treatment outcomes on survival in a population-based cohort of patients with giant cell arteritis.
Color Duplex Sonography for the Diagnosis, Management of Giant Cell Arteritis
The use of color duplex sonography for the diagnosis of patients with suspected giant cell arteritis is associated with high specificity and positive predictive value.
Giant Cell Arteritis Diagnosis in Glucocorticoid-Treated Patients: Utility of PET/CT
The utility of PET and CT imaging to complement temporal artery biopsy in patients with newly diagnosed giant cell arteritis who are receiving glucocorticoid therapy remains equivocal.
FDA Approves First Drug to Specifically Treat Giant Cell Arteritis
Actemra (tocilizumab) has been FDA-approved for its use in giant cell arteritis treatment.
FDA Gives Tocilizumab Priority Review Status for Giant Cell Arteritis
FDA will fast track review of nonsteroidal treatment option for giant cell arteritis.
-
Loading...
-
Loading...
Next post in Vasculitis
